<DOC>
	<DOCNO>NCT01604941</DOCNO>
	<brief_summary>The purpose study evaluate SSP-004184AQ patient transfusional iron overload whose primary diagnosis hereditary congenital anemia . SSP-004184AQ iron chelator development chronic daily oral administration patient transfusional iron overload .</brief_summary>
	<brief_title>Pharmacokinetics SSP-004184 Treatment Chronic Iron Overload Requiring Chelation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Iron Overload</mesh_term>
	<criteria>Willing able sign approve informed consent . Age : 1860 year old , inclusive , Screening . Subjects receive 20 transfusion lifetime transfusional iron overload require chronic treatment iron chelator . N.B . : Sickle Cell Disease subject receive regular exchange transfusion iron overload subject thalassemia intermedia receive regular transfusion ( transfusion dependent thalassemia intermedia ) eligible . Willing discontinue exist iron chelation therapy minimum period one five day prior first dose SSP004184AQ , 24 week duration study 1 week last dose total approximately 26 week . Willing fast two hour prior one hour dose . Serum ferritin &gt; 500ng/mL Screening . Baseline liver iron concentration great equal 5mg iron per g ( equivalent dry weight , liver ) determine FerriScan® R2 MRI . Mean previous three pretransfusion hemoglobin concentration great equal 7.5g/dL . Adult female subject : 1 . Postmenopausal ( 12 consecutive month spontaneous amenorrhea ) , 2 . Surgically sterile , 3 . Females childbearing potential must negative betaHCG pregnancy test Screening Visit negative urine pregnancy test Baseline Visit . Females childbearing potential must agree abstain sexual activity could result pregnancy agree use acceptable method contraception . As result medical review , physical examination , Screening investigation , Principal Investigator ( PI ) considers subject unfit study . Nonelective hospitalization within 30 day prior Baseline test . Evidence clinically relevant oral , cardiovascular , gastrointestinal , hepatic , biliary , renal , endocrine , pulmonary , neurologic , psychiatric , immunologic , bone marrow , skin disorder contraindicates dose SSP004184AQ . Iron overload cause transfusional siderosis . Evidence severe renal insufficiency , eg , serum creatinine 1.5X upper limit normal proteinuria great 1 gm per day calculate glomerular filtration rate &lt; 60mL/min . Severe iron overload include : 1 . T2* MRI &lt; 10 m 2. liver iron concentration FerriScan R2 MRI &gt; 30mg/g liver ( dw ) Known sensitivity magnesium stearate , croscarmellose sodium SSP004184AQ . Platelet count 100,000/μL absolute neutrophil count le 1500/mm3 Screening . Insufficient venous access precludes prescribe blood draw safety laboratory assessment . ALT Screening &gt; 200 IU/L . Use investigational agent within 30 day prior Baseline test . Pregnant lactating female . Cardiac leave ventricular ejection fraction 1 . Below locally determine normal range 12 month prior Screening echocardiograph MRI 2 . &lt; 50 % Baseline testing MRI ( echocardiograph acceptable LVEF MRI information available ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>